Your browser is no longer supported. Please, upgrade your browser.
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.48 Insider Own1.50% Shs Outstand119.10M Perf Week-7.44%
Market Cap132.24M Forward P/E12.44 EPS next Y0.09 Insider Trans0.00% Shs Float116.72M Perf Month-20.00%
Income-40.40M PEG- EPS next Q-0.08 Inst Own25.00% Short Float10.54% Perf Quarter-56.76%
Sales5.40M P/S24.49 EPS this Y29.60% Inst Trans1.56% Short Ratio4.19 Perf Half Y-40.11%
Book/sh-0.60 P/B- EPS next Y132.10% ROA-58.30% Target Price- Perf Year-27.74%
Cash/sh0.36 P/C3.08 EPS next 5Y- ROE70.50% 52W Range1.01 - 2.94 Perf YTD-9.68%
Dividend- P/FCF- EPS past 5Y3.00% ROI120.80% 52W High-61.90% Beta0.97
Dividend %- Quick Ratio2.60 Sales past 5Y-22.40% Gross Margin-11.40% 52W Low10.89% ATR0.09
Employees54 Current Ratio2.70 Sales Q/Q40.00% Oper. Margin- RSI (14)33.35 Volatility6.58% 7.60%
OptionableYes Debt/Eq- EPS Q/Q46.70% Profit Margin- Rel Volume0.47 Prev Close1.14
ShortableYes LT Debt/Eq- EarningsMar 15 AMC Payout- Avg Volume2.93M Price1.12
Recom1.70 SMA20-10.11% SMA50-28.32% SMA200-29.09% Volume1,381,719 Change-1.75%
Jul-20-20Downgrade Credit Suisse Neutral → Underperform
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Sep-15-16Reiterated ROTH Capital Buy $11.25 → $15
Aug-05-16Downgrade Stifel Buy → Hold
Oct-30-15Upgrade Jefferies Hold → Buy
Oct-05-15Reiterated ROTH Capital Buy $8.50 → $10.50
Sep-02-15Initiated H.C. Wainwright Buy $8.50
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
May-10-21 04:05PM  
May-06-21 08:30AM  
May-03-21 03:01PM  
Apr-08-21 10:40AM  
Mar-31-21 08:30AM  
Mar-29-21 09:19AM  
Mar-25-21 08:30AM  
Mar-22-21 02:48PM  
Mar-21-21 09:53PM  
Mar-18-21 04:43PM  
Mar-16-21 10:06PM  
Mar-15-21 05:15PM  
Mar-14-21 09:50PM  
Mar-12-21 05:45AM  
Mar-09-21 10:30PM  
Mar-08-21 04:05PM  
Mar-07-21 05:56PM  
Mar-03-21 03:00AM  
Feb-22-21 01:46PM  
Feb-20-21 07:00PM  
Feb-18-21 09:47PM  
Feb-17-21 08:30AM  
Feb-04-21 11:40PM  
Jan-26-21 10:04AM  
Jan-20-21 09:00AM  
Jan-19-21 04:01PM  
Jan-14-21 08:30AM  
Jan-13-21 10:30AM  
Jan-12-21 11:39AM  
Dec-10-20 09:00AM  
Dec-09-20 12:20PM  
Dec-04-20 08:30AM  
Dec-02-20 10:58AM  
Nov-18-20 08:30AM  
Nov-07-20 07:08AM  
Nov-06-20 01:28PM  
Nov-05-20 08:20PM  
Oct-29-20 04:05PM  
Oct-28-20 12:33PM  
Oct-21-20 10:46AM  
Oct-15-20 10:26AM  
Oct-13-20 12:00PM  
Oct-12-20 08:59AM  
Sep-29-20 08:30AM  
Sep-23-20 06:48AM  
Sep-22-20 08:30AM  
Sep-14-20 08:30AM  
Sep-10-20 04:05PM  
Aug-31-20 05:00PM  
Aug-24-20 08:30AM  
Aug-19-20 08:30AM  
Aug-11-20 12:00PM  
Aug-10-20 05:45PM  
Aug-03-20 04:05PM  
Jul-27-20 12:31PM  
Jul-25-20 08:02AM  
Jul-23-20 08:40AM  
Jun-22-20 10:11PM  
Jun-17-20 06:33AM  
Jun-08-20 02:45PM  
Jun-04-20 08:13AM  
Jun-03-20 06:50PM  
Jun-01-20 08:00PM  
May-29-20 02:34PM  
May-27-20 09:54AM  
May-12-20 03:00AM  
May-11-20 06:45PM  
May-10-20 03:40PM  
May-08-20 12:00PM  
May-07-20 12:55PM  
May-06-20 12:30PM  
May-05-20 12:51PM  
May-04-20 04:35PM  
May-02-20 08:08AM  
Apr-30-20 06:00AM  
Apr-24-20 06:11AM  
Apr-23-20 09:09AM  
Apr-16-20 12:02PM  
Apr-02-20 12:28PM  
Apr-01-20 08:18AM  
Mar-27-20 12:00PM  
Mar-18-20 06:05AM  
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angotti Vincent J.Chief Executive OfficerJun 15Buy1.337,54710,035468,757Jun 15 06:00 PM